company background image
RHOV

RhoVac NGM:RHOVAC Stock Report

Last Price

kr0.49

Market Cap

kr9.4m

7D

-10.0%

1Y

-97.8%

Updated

03 Oct, 2022

Data

Company Financials
RHOVAC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

RHOVAC Stock Overview

RhoVac AB, a pharmaceutical company, develops and commercializes drugs for the treatment of cancer in Sweden and Denmark.

RhoVac AB Competitors

Price History & Performance

Summary of all time highs, changes and price drops for RhoVac
Historical stock prices
Current Share Pricekr0.49
52 Week Highkr38.00
52 Week Lowkr0.47
Beta1.12
1 Month Change-20.29%
3 Month Change-50.99%
1 Year Change-97.78%
3 Year Change-96.96%
5 Year Change-91.47%
Change since IPO-96.43%

Recent News & Updates

Shareholder Returns

RHOVACSE BiotechsSE Market
7D-10.0%12.7%1.9%
1Y-97.8%-29.8%-26.1%

Return vs Industry: RHOVAC underperformed the Swedish Biotechs industry which returned -31.3% over the past year.

Return vs Market: RHOVAC underperformed the Swedish Market which returned -27.6% over the past year.

Price Volatility

Is RHOVAC's price volatile compared to industry and market?
RHOVAC volatility
RHOVAC Average Weekly Movement12.8%
Biotechs Industry Average Movement8.1%
Market Average Movement6.9%
10% most volatile stocks in SE Market11.6%
10% least volatile stocks in SE Market4.3%

Stable Share Price: RHOVAC is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: RHOVAC's weekly volatility has decreased from 19% to 13% over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
20073Lars Hedbyshttps://www.rhovac.com

RhoVac AB, a pharmaceutical company, develops and commercializes drugs for the treatment of cancer in Sweden and Denmark. Its primary product candidate is RV001, an immuno-oncologic drug, which is in phase IIb clinical phase to identify and destroy cells that carry metastatic or metastatic potential cells. The company was founded in 2007 and is headquartered in Lund, Sweden.

RhoVac AB Fundamentals Summary

How do RhoVac's earnings and revenue compare to its market cap?
RHOVAC fundamental statistics
Market Capkr9.43m
Earnings (TTM)-kr67.60m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RHOVAC income statement (TTM)
Revenuekr0
Cost of Revenuekr0
Gross Profitkr0
Other Expenseskr67.60m
Earnings-kr67.60m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.55
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did RHOVAC perform over the long term?

See historical performance and comparison